AstraZeneca Results Presentation Deck slide image

AstraZeneca Results Presentation Deck

12 Capital allocation Capital allocation strategy unchanged Reinvestment in the business | Free cashflow post-Capex Maintain a strong investment- grade credit rating CEO Opening Remarks Value- enhancing business development CAPEX = capital expenditure; YTD = year-to-date. Progressive dividend policy Priority remains reinvesting in our business Financial Results ā— Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Investments to drive future growth Currently >120 projects in Phase II/III development Investments behind launches in new indications and strengthening leadership in existing therapy areas Continued investments in new technologies and platforms including cell and gene therapies Value accretive deals Continue to leverage partnerships to drive innovation and bring medicines to markets quicker >20 new approvals in major markets YTD
View entire presentation